Menu
Washingtoner
  • Home
  • Health
  • Artificial Intelligence
  • Technology
  • Real Estate
  • Entertainment
  • Information Technology
  • Concealed Carry
  • Software
Washingtoner

Seagen Statement on Outcome of Daiichi Sankyo Arbitration
Washingtoner/10182820

Trending...
  • Spokane: Impacts For Final Stretch of Construction Season
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties' 2008 collaboration agreement for the use of Seagen's antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.

"While we are disappointed with the arbitration decision, it was important for us to pursue this legal action," said Roger Dansey, M.D., interim Chief Executive Officer and Chief Medical Officer, Seagen. "This does not impact our existing business. Looking forward, we are well-positioned to drive continued innovation and growth with four commercial products and a deep and diverse pipeline of promising programs. Seagen remains focused on developing innovative medicines that make a meaningful difference in the lives of cancer patients."

More on Washingtoner
  • JaapDaily passes 22 million chants, adds big-screen Recite Along view for Navratri
  • valueGLASS Calls for Independent Choice as Safelite Absorbs Kitsap Competitor
  • Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
  • Tacoma: Community Event Funding Announced for 2027
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago

About Seagen

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people's lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company's marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to Seagen's continued innovation and growth, as well as its pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, the risk that the company's financial results may not be as expected and the difficulty and uncertainty of pharmaceutical product development. More information about the risks and uncertainties faced by the company is contained under the caption "Risk Factors" included in Seagen's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise except as required by applicable law.

More on Washingtoner
  • Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
  • Save 15 Percent Off Florida Keys Accommodations with KeysCaribbean's Advance Purchase Rate Discount
  • Woodside Rehab & Nursing Enters a New Era of Clinical Excellence and Growth
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe

Contacts

For Media

David Caouette
(310) 430-3476
dcaouette@seagen.com

For Investors
Peggy Pinkston
(425) 527-4160
ppinkston@seagen.com
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on Washingtoner
  • Tacoma: Nominations Open for 2027 Dr. Martin Luther King, Jr. Community Service Awards
  • Solid Earth's new "Welcome to Real Estate" campaign introduces RealtyID™: Know Before Your Open the Door
  • Radio Drive's New Album Walk With Me Delivers Two GRAMMY® Submissions Across Rock and Alternative Categories
  • Kaplan Morrell and Attorney Jacqui Condon Selected to Represent Professional Women's Soccer Players in Workers' Compensation Matters
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • JEGS Launches Transformed Digital Commerce Platform Powered by PhaseZero
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Cummings Graduate Institute Celebrates New Doctor of Behavioral Health Graduates
  • Visit London Appoints The SEO Works for AI-First Search Strategy
  • Spokane: Parks & Recreation Secures Top Ranking for $4.6M in State Grant Match
  • City of Spokane to Install First 'Emergency Streets' Lane Closure After Weekend Fatal Crash
  • Inglewood Associates and Gordon Brothers Provide Update on Sale Process for 925 Euclid Avenue in Cleveland
  • Century Fasteners Corp. Exhibiting at the 2026 International Fastener Expo
  • Las Vegas Attorney Thomas Boley Publishes Free Plain-English Guide to 100 Nevada Criminal Laws, in English and Spanish
  • Tacoma: 'Preparing the Bid' Workshop on October 19
  • Tacoma: Street Operations Crew Scheduled to Conduct Snow and Ice Training October 12 – 14
  • Bank Statement Loans Up to $30 Million: Lendmire Announces High-Net-Worth Financing
_catLbl0 _catLbl1

Popular on Washingtoner

  • 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses - 147
  • Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs - 147
  • DuoKey launches the World's First Agentic Crypto Agility Platform - 135
  • Dr. Pen Official Introduces Advanced Microneedling Technology for Precision Skincare at Home - 112
  • Marti Reeder Ranked Among Washington State's Top Real Estate Brokers by RealTrends Verified - 105
  • Applicants Sought for Tacoma Public Library Board of Trustees
  • DAZN Review 2026: Streaming Price Worth It?
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again
  • RAS AP Consulting Spotlights Managed AP Governance™ at Esker All Access
  • Continuous You Foundation Announces Partnership with Haawke Neural Technology

Similar on Washingtoner

  • Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
  • PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
  • Your Local Pro Expands National Service Network to 273+ Locations Across Plumbing, Cleaning, Landscaping and Hydrovac
  • Acuvance Coker Study Finds Experience, Not Supply, Is the Biggest Advanced Practice Provider Workforce Challenge
  • Uk Financial Moonshot Token™ Robinhood-chain Goes Live On Tokpie Exchange Tomorrow, With Solana Side Of UKFLMS To Follow In Global Listing Expansion
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Revenue Optics Names Prat Patibandla Director of Growth Marketing
Copyright © 2026 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute